News
-
Fewer Biopsies Go to Pathology Labs when Gastroenterologists Use New Miniature Microscope
Darkdaily.com: Advances in use of probe-based Confocal Laser Endomicroscopy (pCLE) could mean that GIs refer fewer specimens to clinical pathology laboratories.29/11/2011
more
-
The Cellvizio App is Here
Discover state-of-the-art medical imaging technology via the Cellvizio App. Connect with the Cellvizio® community through the calendar, activate notifications to stay up to date on upcoming workshops and live shows, and browse the library of sample Cellvizio videos.28/11/2011
more
-
World's Smallest Microscope Improves GI Disease Detection and Speeds Treatment at Lankenau Medical Center in Philadelphia
Lankenau Medical Center GI physicians are the first in the Philadelphia area to use the world's smallest flexible microscope to diagnose GI and biliary diseases during regular endoscopy procedures so patients can be treated immediately. This new tool, known as probe-based Confocal Laser Endomicroscopy (pCLE) or "Cellvizio," allows them to view living, moving tissue in real time at the cellular level so they can precisely pinpoint tissue that should be removed or treated.03/11/2011
more
-
Mauna Kea Technologies Cellvizio Endomicroscopy System Received FDA Clearance
Mauna Kea Technologies has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the next-generation endomicroscopy system for the GI and pulmonary tracts, called the Cellvizio 100 Series. Launched in Europe after obtaining the CE mark in April 2011, the Cellvizio 100 Series is now ready to be released in the United States.02/09/2011
more
-
Cellvizio 100 Series Endomicroscopy System Obtains 510(k) Clearance from FDA
Cellvizio, the probe-based microscope provides real-time images of tissue at the cellular level while a physician is performing a procedure such as an endoscopy or bronchoscopy. The microscopic imaging may potentially improve detection of pre-cancerous lesions.01/09/2011
more
-
FDA Okays Mauna Kea's Updated Cellvizio Endomicroscopy System for GI Tracts
Mauna Kea Technologies has obtained FDA clearance for its updated Cellvizio endomicroscopy system for the GI and pulmonary tracts, according to a company release. New features of the new Cellvizio 100 Series include improvements in endomicroscopic image acquisition and interpretation.31/08/2011
more
-
Mauna Kea Technologies Gets FDA Clearance for Cellvizio System
Mauna Kea Technologies , a company in the endomicroscopy market, announced that it has obtained 510(k) clearance (N degrees K111047) from the U.S. Food and Drug Administration (FDA) to market the next-generation endomicroscopy system for the GI and pulmonary tracts, called the Cellvizio 100 Series.30/08/2011
more
-
Mauna Kea Technologies receives FDA approval for its Cellvizio 100 Series
Mauna Kea Technologies received FDA clearance for its next-generation endomicroscopy system - Cellvizio 100 Series to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts.30/08/2011
more
-
13/04/2012
The 4th International Conference of Cellvizio Users (ICCU)
Under the chairmanship of Pr. Kenneth Chang (University of California, Irvine, United States) and Dr. Bertrand Napoléon (Hopital privé Jean Mermoz, Lyon, France), a new format with a scientific program will be presented to the expanding Cellvizio users community which includes GI endoscopists, pulmonologists, urologists and surgeons.
-
15/03/2012
JFHOD 2012: French-speaking days of Digestive Hepato-gastroenterology and Oncology
A French-speaking congress of reference in terms of digestive cancers and diseases gathering 4000 participants each year.
See all events
-
17/02/2012
Cellvizio GI Workshop: Cochin Hospital, Paris, France
Cellvizio Live procedures and pCLE image interpretation training. Trainers: Prof. F. Prat and Dr. S. Leblanc. Register now: http://www.cellvizio.net/contact-us
See all training opportunities
-
21/10/2011
Cellvizio News, October 2011
It would be an understatement to say that our IPO is a major milestone in the life of our company. Its success – the largest IPO in France since early 2010 - is commensurate with the effort we have put into developing our ground-breaking technology and we are extremely happy to be in a position to take it to the next phase and to think very long term.more
See all newsletters
-
07/02/2012
ADMISSION OF THE MAUNA KEA TECHNOLOGIES SHARE TO THE SRD “LONG”
Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), leader in the endomicroscopy market, today announces the upcoming admission of its share to the “SRD Long-Only” of the Deferred Settlement Service.
Read all our press releases
